Hot Features
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engi... Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.345 | -15.9722222222 | 2.16 | 2.16 | 1.75 | 8202592 | 1.95889419 | CS |
| 4 | -0.475 | -20.7423580786 | 2.29 | 2.3899 | 1.75 | 7487874 | 2.07619335 | CS |
| 12 | -0.635 | -25.9183673469 | 2.45 | 4.46 | 1.75 | 10391136 | 2.35476306 | CS |
| 26 | 0.385 | 26.9230769231 | 1.43 | 4.46 | 1.295 | 7521611 | 2.18388687 | CS |
| 52 | 0.365 | 25.1724137931 | 1.45 | 4.46 | 0.9842 | 5400641 | 1.88417845 | CS |
| 156 | -3.985 | -68.7068965517 | 5.8 | 6.05 | 0.8621 | 3725997 | 2.37370758 | CS |
| 260 | -23.265 | -92.7631578947 | 25.08 | 27.86 | 0.8621 | 2928730 | 4.51823649 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.